References
- Agarawal JP, Swangsilpa T, van der Linden Y, Rades D, Jeremic B, Hoskin PJ. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 2006; 18: 747-60. doi: 10.1016/j. clon.2006.09.007
- De Felice F, Piccioli A, Musio D, Tombolini V. The role of radiation therapy in bone metastases management. Oncotarget 2017; 8: 25691-9. doi: 10.18632/oncotarget.14823
- Spencer KL, van der Velden JM, Wong E, Seravalli E, Sahgal A, Chow E, et al. Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst 2019; 111: 1023-32. doi: 10.1093/jnci/djz101
- Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J Bone Miner Res 2018; 33: 2099-113. doi: 10.1002/jbmr.3618
- Pontoriero A, Lillo S, Caravatta L, Bellafiore F, Longo S, Lattanzi E, et al. Cumulative dose, toxicity, and outcomes of spinal metastases re-irradiation. Strahlenther Onkol 2021; 197: 369-84. doi: 10.1007/s00066-021-01748-7
- Turpin A, Duterque-Coquillaud M, Vieillard MH. Bone metastasis: current state of play. Transl Oncol 2020; 13: 308-20. doi: 10.1016/j.tranon.2019.10.012
- Tang X, Hu Q, Chen Y, Wang X, Li X, Cheng K, et al. Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis. BMJ Open 2020; 10: e033120. doi: 10.1136/bmjopen-2019-033120
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10. doi: 10.1200/JCO.1995.13.1.8
- Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol 2017; 14: 15-25. doi: 10.1038/nrurol.2016.175
- Hurmuz P, Onal C, Ozyigit G, Igdem S, Atalar B, Sayan H, et al. Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002). Strahlenther Onkol 2020; 196: 1034-43. doi: 10.1007/s00066-020-01660-6
- Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer 2019; 125: 340-52. doi: 10.1002/cncr.31860
- Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol 2014; 11: 549-57. doi: 10.1038/nrclinonc.2014.96
- Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, et al. What is oligometastatic prostate cancer? Eur Urol Focus 2019; 5: 159-61. doi: 10.1016/j.euf.2018.12.009
- Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36: 446-53. doi: 10.1200/JCO.2017.75.4853
- Hoskin PJ, Yarnold JR, Roos DR, Bentzen S, Second Workshop on Palliative R, Symptom C. Radiotherapy for bone metastases. Clin Oncol (R Coll Radiol) 2001; 13: 88-90. doi: 10.1053/clon.2001.9225
- Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic N, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 2005; 23: 3366-75. doi: 10.1200/JCO.2005.04.754
- Jaffray D, Kupelian P, Djemil T, Macklis RM. Review of image-guided radiation therapy. Expert Rev Anticancer Ther 2007; 7: 89-103. doi: 10.1586/14737140.7.1.89
- Lee YK, Bedford JL, McNair HA, Hawkins MA. Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost. Br J Radiol 2013; 86: 20120466. doi: 10.1259/bjr.20120466
- Lubgan D, Ziegaus A, Semrau S, Lambrecht U, Lettmaier S, Fietkau R. Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results. Strahlenther Onkol 2015; 191: 264-71. doi: 10.1007/s00066-014-0780-4
- Guckenberger M, Mantel F, Sweeney RA, Hawkins M, Belderbos J, Ahmed M, et al. Long-term results of dose-intensified fractionated stereotactic body radiation therapy (SBRT) for painful spinal metastases. Int J Radiat Oncol Biol Phys 2021; 110: 348-57. doi: 10.1016/j.ijrobp.2020.12.045
- Sprave T, Welte SE, Bruckner T, Förster R, Bostel T, Schlampp I, et al. Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial. Trials 2018; 19: 59. doi: 10.1186/s13063-018-2452-7
- Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): S42-9. doi: 10.1016/j.ijrobp.2009.04.095
- de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol 2014; 25: 467-71. doi: 10.1093/annonc/mdt537
- Guckenberger M, Mantel F, Gerszten PC, Flickinger JC, Sahgal A, Letourneau D, et al. Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol 2014; 9: 226. doi: 10.1186/s13014-014-0226-2
- Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017; 7: 4-12. doi: 10.1016/j.prro.2016.08.001
- Fujino M, Suzuki K, Nishio M, Nishiyama N, Osaka Y. Strategy of radiation therapy for bone metastases and MSCC in breast cancer patients. Breast Cancer 2011; 18: 238-43. doi: 10.1007/s12282-011-0288-z
- Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, 3rd, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798-804. doi: 10.1093/jnci/dji139
- Hölscher T, Baumann M, Kotzerke J, Wirth M, Thomas C, Zips D, et al. OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oli-gometastatic prostate cancer – a phase II trial. [abstract]. J Clin Oncol 2021; 39(6 Suppl): 115. doi: 10.1200/JCO.2021.39.6_suppl.115
- Rades D, Panzner A, Rudat V, Karstens JH, Schild SE. Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis. Strahlenther Onkol 2011; 187: 729-35. doi: 10.1007/s00066-011-2266-y
- Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine 2009; 34(22 Suppl): S78-92. doi: 10.1097/BRS.0b013e3181b8b6f5
- Makita K, Hamamoto Y, Kanzaki H, Kataoka M, Yamamoto S, Nagasaki K, et al. Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. Radiat Oncol 2021; 16: 225. doi: 10.1186/s13014-021-01940-0
- Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases – secondary results of a randomized trial. Radiat Oncol 2018; 13: 212. doi: 10.1186/s13014-018-1161-4